Sotalol hydrochloride

Base Information

• Chemical Name: Sotalol hydrochloride
• CAS No.: 959-24-0
• Molecular Formula: C12H20N2O3S^.HCl
• Molecular Weight: 308.829
• Hs Code.: 2935904000
• European Community (EC) Number: 213-496-0
• NSC Number: 760358,337251
• UNII: HEC37C70XX
• DSSTox Substance ID: DTXSID8021278
• Wikidata: Q27108309
• NCI Thesaurus Code: C29463
• RXCUI: 7008
• Metabolomics Workbench ID: 53441
• ChEMBL ID: CHEMBL1700
• Mol file: 959-24-0.mol

Synonyms:Darob;MJ 1999;MJ-1999;MJ1999;Sotalol;Sotalol Hydrochloride;Sotalol Monohydrochloride

Chemical Property of Sotalol hydrochloride

Chemical Property:

• Appearance/Colour: white crystalline solid
• Melting Point: 218-220 °C
• Boiling Point: 443.3 °C at 760 mmHg
• Flash Point: 221.9 °C
• PSA: 86.81000
• LogP: 3.43620
• Storage Temp.: Store at RT
• Solubility.: H2O: 20 mg/mL
• Water Solubility.: Soluble in phosphate buffered saline, DMSO, ethanol, water, and methanol.
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 6
• Exact Mass: 308.0961414
• Heavy Atom Count: 19
• Complexity: 330

Purity/Quality:

98% ^*data from raw suppliers

Sotalol hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi
• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O.Cl
• Recent ClinicalTrials: Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ?, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting Conditions
• Recent EU Clinical Trials: Pulmonary vein isolation with versus without continued antiarrhythmic drug treatment in subjects with persistent atrial fibrillation: a prospective multi-centre randomized controlled clinical study (POWDER-AF2 study)
• Description: Sotalol is a non-selective antagonist of β-adrenergic receptors (β-ARs; IC50s = 8.9 and 5.2 μM for β1- and β2-ARs, respectively) and a class III antiarrhythmic agent. It decreases delayed outward potassium currents (IK) in guinea pig ventricular cells and prolongs action potential duration in electrically stimulated isolated guinea pig papillary muscles when used at a concentration of 100 μM. Sotalol decreases heart rate and increases blood pressure and the cardiac functional refractory period (FRP) in a canine model of ventricular tachycardia induced by programmed electrical stimulation (PES). Formulations containing sotalol have been used in the treatment of ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL). Sotalol (hydrochloride) (Item No. 26291) is an analytical reference standard categorized as a β-adrenergic receptor antagonist. It has been detected as an adverse analytical finding (AAF) during anti-doping testing. This product is intended for use in analytical forensic applications. This product is also available as a general research tool .
• Uses: Sotalol hydrochloride is used as a potent beta adrenergic antagonist, prolongs the action potential and increases the refractory period. Sotalol hydrochloride is also considered a non-selective β blocker and a potassium channel blocker with an IC50 of 43 μM. A potent -adrenergic receptor antagonist. A class III antiarrythmic. It has been shown to prolong action potential and increases the refractory period A potent α-adrenergic receptor antagonist. A class III antiarrythmic. It has been shown to prolong action potential and increases the refractory period. antibacterial
• Clinical Use: Beta-adrenoceptor blocker: Treatment of life-threatening ventricular arrhythmias Prophylaxis of SVT
• Drug interactions: Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: NSAIDs antagonise hypotensive effect. Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk ofbradycardia, myocardial depression and AV block with amiodarone; increased risk of ventricular arrhythmias with amiodarone, dronedarone, disopyramide or procainamide - avoid; increased risk of myocardial depression and bradycardia with flecainide. Antibacterials: increased risk of ventricular arrhythmias with moxifloxacin - avoid; increased risk of ventricular arrhythmias with delamanid. Antidepressants: enhanced hypotensive effect with MAOIs; increased risk of ventricular arrhythmias with tricyclics; increased risk of ventricular arrhythmias with citalopram, escitalopram and venlafaxine - avoid. Antihistamines: increased risk of ventricular arrhythmias with mizolastine - avoid. Antihypertensives: enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin. Antimalarials: increased risk of bradycardia with mefloquine; avoid with artemether and lumefantrine and piperaquine with artenimol - increased risk of ventricular arrhythmias. Antimuscarinics: increased risk of ventricular arrhythmias with tolterodine. Antipsychotics: enhanced hypotensive effect with phenothiazines; increased risk of ventricular arrhythmias with amisulpride, droperidol, haloperidol, phenothiazines, pimozide, risperidone, sulpiride or zuclopenthixol - avoid with droperidol and zuclopenthixol. Antivirals: increased risk of ventricular arrhythmias with saquinavir or telaprevir - avoid. Atomoxetine: increased risk of ventricular arrhythmias. Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil. Cytotoxics: possible increased risk of bradycardia with crizotinib; increased risk of ventricular arrhythmias with vandetanib - avoid; increased risk of ventricular arrhythmias with arsenic trioxide, bosutinib, ceritinib, panobinostat and vandetanib. Diuretics: enhanced hypotensive effect; increased risk of ventricular arrhythmias due to hypokalaemia. Fingolimod: possibly increased risk of bradycardia. Ivabradine: increased risk of ventricular arrhythmias. Moxisylyte: possible severe postural hypotension. Ranolazine: avoid concomitant use. Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.

Technology Process of Sotalol hydrochloride

There total 1 articles about Sotalol hydrochloride which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ sotalol hydrochloride (959-24-0,1026-89-7,4549-94-4)

Guidance literature:

Reference yield: 87.0%

sotalol hydrochloride (959-24-0,1026-89-7,4549-94-4) → N-nitrososotalol (134720-07-3)

Guidance literature:

With hydrogenchloride; sodium nitrite; at 50 ℃; for 6h;

Downstream raw materials:

N-nitrososotalol

Refernces